Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Over the past two years, a wave of ICH updates including ICH M13A, ICH M12, ICH E11A, and the emerging ICH M15 has accelerated the shift toward global alignment and model-informed drug development (MIDD).

But regulators are no longer asking whether guidance has been followed.

They are asking whether your evidence is credible.

That means:

• Is your modeling grounded in physiology?
• Does your clinical data reinforce your assumptions?
• Does your evidence form a coherent, defensible narrative?

A submission can be technically complete and still fail if it lacks scientific coherence.

Harmonization is advancing, particularly with ICH M15, which aims to standardize how model-informed drug development is evaluated globally.

However, regional differences remain.

Regulators still diverge on:

• Acceptable levels of model reliance
• Regional considerations such as enzyme polymorphisms
• Expectations for clinical confirmation

The result is clear. Sponsors can align their clinical pharmacology strategy globally but must still plan for regional interpretation of the same data.

Modeling is now central to clinical pharmacology strategy in 2026, but trust is the limiting factor.

Most regulatory pushback is not about model fit. It is about whether the model reflects biological and clinical reality.

The fastest way to lose credibility:

• Parameters outside known physiology
• Overly complex models without justification
• Extrapolations lacking clinical anchoring

A model does not need to be perfect, but it must be mechanistically believable.

Regulators increasingly expect models to sit within a totality of evidence framework, alongside clinical and real-world data.

For drug-drug interaction strategies, particularly under evolving expectations from ICH M12, PBPK modeling is becoming a standard part of efficient development.

Not because regulators require it, but because not using it often results in:

• Additional clinical studies
• Longer timelines
• Increased development costs

Sponsors can proceed without PBPK, but they must demonstrate that the decision is intentional and justified.

Regulators are encouraging NAMs such as:

• AI-based toxicity prediction
• Organoids
• Microphysiological systems

However, these approaches are still evaluated within a weight-of-evidence framework, not as standalone replacements.

The direction is clear, but the evidentiary threshold is still evolving.

A key source of regulatory friction in clinical pharmacology strategy is the disconnect between CMC and clinical pharmacology.

Common issues include:

• Late formulation changes
• Inadequate bridging strategies
• Over-reliance on modeling to rescue failed studies

From a regulatory perspective, these issues raise concerns about data reliability and interpretability.

Integration across functions is no longer optional. It is expected.

Modeling is increasingly shaping trial design, dose selection, and extrapolation strategies, particularly in the context of ICH E11A for pediatric extrapolation.

However, regulators still expect human data, particularly for safety or to confirm modeling outputs.

Pregnant, breastfeeding, and pediatric populations are increasingly included in development. The 2024 Declaration of Helsinki reinforces the importance of minimizing the harms of exclusion.

Regulatory decisions depend on how well modeling, clinical data, and mechanistic understanding align into a unified evidence strategy.

The risk profile has shifted.

In 2026, programs are less likely to fail because of missing data, and more likely to fail because of how that data is interpreted and justified.

Programs are most likely to fail when they:

• Over-model without biological grounding
• Under-justify key assumptions
• Assume harmonization equals alignment

Successful strategies focus on:

• Building credibility, not just completeness
•  Integrating evidence across disciplines
• Anticipating regulatory scrutiny

Upcoming EU pharmaceutical legislation signals a shift toward iterative data generation and adaptive regulatory pathways.

Key developments include:

• Stepwise pediatric development leveraging MIDD and extrapolation
• Regulatory sandboxes enabling validation of innovative approaches such as digital twins and in silico trials

From a clinical pharmacology strategy perspective, this elevates modeling and simulation from a supporting role to a central driver of regulatory decision-making.

Strategic agility will no longer be optional. It will be required.

This webinar was designed as a strategic overview of how regulatory expectations are evolving.

The next step is clear: translating insight into execution.

Part 1 focused on how regulators think. Part 2 will focus on how to apply that thinking in real-world programs.

In Part 2, we will explore:

• What makes a model credible and what leads to regulatory pushback
• How successful MIDD and PBPK strategies are implemented
• Where global alignment breaks down and how to plan for it
• How to manage late-stage risks without delaying approval
• The subtle mistakes that trigger Information Requests

Clinical pharmacology strategy in 2026 is no longer about meeting requirements. It is about building a scientifically credible, integrated evidence narrative.

As expectations evolve, success will depend on how well sponsors align modeling, clinical data, and cross-functional decisions into a strategy that holds up under scrutiny.